ANTIPODES PARTNERS Ltd Lowers Stock Holdings in HCA Healthcare, Inc. $HCA

ANTIPODES PARTNERS Ltd decreased its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 7.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 362,179 shares of the company’s stock after selling 29,279 shares during the period. HCA Healthcare accounts for about 3.5% of ANTIPODES PARTNERS Ltd’s holdings, making the stock its 6th biggest position. ANTIPODES PARTNERS Ltd’s holdings in HCA Healthcare were worth $154,372,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in HCA. Clearstead Trust LLC boosted its holdings in shares of HCA Healthcare by 311.8% in the second quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock worth $27,000 after acquiring an additional 53 shares during the period. Harbor Capital Advisors Inc. grew its position in shares of HCA Healthcare by 82.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 75 shares of the company’s stock valued at $32,000 after purchasing an additional 34 shares in the last quarter. Twin Peaks Wealth Advisors LLC bought a new stake in HCA Healthcare during the second quarter valued at $40,000. Compound Global Advisors LLC purchased a new stake in shares of HCA Healthcare in the 3rd quarter valued at about $44,000. Finally, True Wealth Design LLC grew its holdings in shares of HCA Healthcare by 179.5% during the third quarter. True Wealth Design LLC now owns 109 shares of the company’s stock worth $47,000 after purchasing an additional 70 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Trading Up 0.8%

Shares of HCA opened at $532.98 on Friday. The stock’s 50 day moving average is $488.01 and its two-hundred day moving average is $454.46. HCA Healthcare, Inc. has a twelve month low of $295.00 and a twelve month high of $552.90. The firm has a market capitalization of $119.19 billion, a PE ratio of 18.78, a P/E/G ratio of 1.62 and a beta of 1.36.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Tuesday, January 27th. The company reported $8.01 earnings per share for the quarter, topping analysts’ consensus estimates of $7.37 by $0.64. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The business had revenue of $19.51 billion for the quarter, compared to analysts’ expectations of $19.67 billion. During the same quarter in the prior year, the firm posted $6.22 EPS. The company’s revenue was up 6.7% compared to the same quarter last year. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. On average, sell-side analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 17th will be paid a dividend of $0.78 per share. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.72. This represents a $3.12 annualized dividend and a yield of 0.6%. The ex-dividend date is Tuesday, March 17th. HCA Healthcare’s payout ratio is currently 10.15%.

HCA Healthcare News Roundup

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: HCA is expanding emergency access through local partnerships and new freestanding ERs, which can increase lower‑acuity, higher‑margin volumes and outpatient revenue. Read More.
• Positive Sentiment: HCA opened a new ER site (Shoppes at Mission Trace) — incremental access points support ambulatory/ER growth. Read More.
• Positive Sentiment: Analyst and momentum coverage is favorable: Zacks highlights HCA as a momentum name and JPMorgan raised its price target to $535 (neutral rating but higher target), both of which can attract investor flows. Read More. — Read More.
• Neutral Sentiment: Local human‑interest/community health stories (neonatal success, suicide‑prevention grant) are positive for brand but unlikely to move the stock materially. Read More. — Read More.
• Neutral Sentiment: Leadership moves (new chief nurse in Houston; four new leaders in Alaska) are operational/clinic-level changes that support execution but are not major catalysts on their own. Read More. — Read More.
• Negative Sentiment: A nurse sued HCA Florida Palms West Hospital and a security company after a violent patient attack — litigation and safety concerns can raise reputational risk and potential costs. Read More.
• Negative Sentiment: Critical opinion pieces highlight continued safety concerns at Mission Hospital; sustained negative media about safety can pressure sentiment and invite regulatory/survey scrutiny. Read More.
• Negative Sentiment: Insider selling disclosed: EVP Michael McAlevey sold ~1,694 shares (~$903K). While single insider sales often reflect personal liquidity, markets sometimes view such moves as a minor negative signal. Read More.

Insider Buying and Selling at HCA Healthcare

In other news, EVP Michael R. Mcalevey sold 1,694 shares of HCA Healthcare stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $533.37, for a total transaction of $903,528.78. Following the sale, the executive vice president owned 8,853 shares in the company, valued at $4,721,924.61. This trade represents a 16.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Christopher F. Wyatt sold 4,000 shares of HCA Healthcare stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $505.00, for a total transaction of $2,020,000.00. Following the completion of the sale, the senior vice president owned 44,379 shares of the company’s stock, valued at approximately $22,411,395. This trade represents a 8.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 15,214 shares of company stock worth $7,797,595 over the last three months. 1.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

HCA has been the topic of a number of research analyst reports. Stephens increased their target price on HCA Healthcare from $450.00 to $500.00 and gave the company an “overweight” rating in a research note on Monday, October 27th. Deutsche Bank Aktiengesellschaft increased their price target on shares of HCA Healthcare from $500.00 to $558.00 and gave the company a “buy” rating in a research report on Wednesday, January 28th. Oppenheimer lifted their price objective on HCA Healthcare from $500.00 to $540.00 and gave the stock an “outperform” rating in a report on Wednesday, January 28th. Wall Street Zen cut HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Finally, Bank of America increased their price target on shares of HCA Healthcare from $430.00 to $470.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. Sixteen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $530.77.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.